|
In € millions, except earnings per share and dividend (in €) |
2015
|
2016 |
2017 | 2018 | 2019 |
|---|---|---|---|---|---|
|
Order intake |
18,880 | 16,514 | 14,920 | 16,034 | 19,142 |
|
Order book at end of period |
32,292 | 33,530 | 31,914 |
32,329 |
33,839 |
Sales |
14,063 |
14,885 |
15,795 |
15,855 |
18,401 |
| Total change | + 8.4% | + 5.8% | + 6.1% |
+4.1% |
+16.1% |
| Organic change | + 4.5% | + 6.8% | + 7.2% | +5.3% | +0.8% |
EBIT (1) |
1,216 |
1,354 |
1,543 | 1,685 | 2,008 |
| In % of sales | 8.6% | 9.1% | 9.8% | 10.6% | 10.9% |
Adjusted net income , Group share (1) |
809 |
897 |
982 | 1,178 | 1,405 |
Consolidated net income, Group share |
765 | 946 | 822 | 982 | 1,122 |
Adjusted net income Group share, per share (EPS)(1) |
3.89 |
4.25 |
4.64 | 5.55 | 6.61 |
Dividend per share |
1.36 | 1.60 | 1.75 | 2.08 | 0.60(2) |
Free operating cash-flow (1) |
1,110 |
954 |
1,365 | 811 | 1,372 |
Net cash position (debt) at end of period |
1,978 | 2,366 | 2,971 | 3,181 | -3,311 |
Self-funded R&D |
692 |
731
|
797 | 879 | 1,097 |
Consolidated headcount at year-end |
62,194 | 64,071 | 64,860 | 66,135 | 82,605 |
- (1) Non-GAAP measures. See definitions in the corresponding reference documents.
- (2) Amount adjusted down in the context of the Covid-19 crisis. Initial amount: €2.65
Contact
Investors relations
+33 (0) 1 57 77 89 02
ir@thalesgroup.com